Showing results (161-170 of 174) with videos related to
Sort By:
Pageof 18
European Journal of Cancer (Oxford, England : 1990)|April 21, 2026
Evolving landscape of targeted therapies in early phase clinical trialsAlice Rossi, Irene Braña, Maria Vieito, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2026
A first-in-human phase 1 clinical trial evaluating clinical activity and proof-of-mechanism of tobemstomig, a PD1-LAG3 bispecific antibody, in patients with CPI-experienced melanomaElena Garralda, Christoph Markert, Victor Moreno, et al.The European Respiratory Journal|July 2, 2021
Risk factors for post-COVID-19 condition in previously hospitalised children using the ISARIC Global follow-up protocol: a prospective cohort studyIsmail M Osmanov, Ekaterina Spiridonova, Polina Bobkova, et al.Med (New York, N.Y.)|August 12, 2023
A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trialsAlberto Hernando-Calvo, Maria Vila-Casadesús, Yacine Bareche, et al.Cancer Discovery|February 17, 2022
Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid TumorsAlexander Muik, Elena Garralda, Isil Altintas, et al.The Lancet Regional Health. Europe|November 12, 2024
Development of a prognostic model to predict 90-day mortality in hospitalised cancer patients (PROMISE tool): a prospective observational studyOriol Mirallas, Berta Martin-Cullell, Víctor Navarro, et al.Cancer Discovery|June 13, 2024
Cancer Core Europe: Leveraging Institutional Synergies to Advance Oncology Research and Care GloballyJavier Carmona, Elena Chavarria, Kate Donoghue, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 16, 2025
Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with ImmunotherapyElena Garralda, Charles Abbott, Alma Calahorro, et al.Journal of Hematology & Oncology|July 10, 2026
Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumorsIgnacio Melero, María de Miguel, Elena Garralda Cabanas, et al.The New England Journal of Medicine|August 27, 2020
Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung CancerAlexander Drilon, Geoffrey R Oxnard, Daniel S W Tan, et al.Pageof 18